154 related articles for article (PubMed ID: 29089368)
41. The thyrotropin receptor as a model to illustrate receptor and receptor antibody diseases.
Ludgate ME; Vassart G
Baillieres Clin Endocrinol Metab; 1995 Jan; 9(1):95-113. PubMed ID: 7726800
[TBL] [Abstract][Full Text] [Related]
42. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.
Krieger CC; Boutin A; Jang D; Morgan SJ; Banga JP; Kahaly GJ; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Endocrinology; 2019 Jun; 160(6):1468-1479. PubMed ID: 31127272
[TBL] [Abstract][Full Text] [Related]
43. Regulation of thyrotropin receptor gene expression in 3T3-L1 adipose cells is distinct from its regulation in FRTL-5 thyroid cells.
Shimura H; Haraguchi K; Endo T; Onaya T
Endocrinology; 1997 Apr; 138(4):1483-90. PubMed ID: 9075706
[TBL] [Abstract][Full Text] [Related]
44. The human thyrotropin receptor is predominantly internalized by beta-arrestin 2.
Frenzel R; Voigt C; Paschke R
Endocrinology; 2006 Jun; 147(6):3114-22. PubMed ID: 16513835
[TBL] [Abstract][Full Text] [Related]
45. TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities.
Sanders J; Miguel RN; Furmaniak J; Smith BR
Methods Enzymol; 2010; 485():393-420. PubMed ID: 21050929
[TBL] [Abstract][Full Text] [Related]
46. The thyroid disruptor 1,1,1-trichloro-2,2-bis(p-chlorophenyl)-ethane appears to be an uncompetitive inverse agonist for the thyrotropin receptor.
Rossi M; Dimida A; Dell'anno MT; Trincavelli ML; Agretti P; Giorgi F; Corsini GU; Pinchera A; Vitti P; Tonacchera M; Maggio R
J Pharmacol Exp Ther; 2007 Jan; 320(1):465-74. PubMed ID: 17062616
[TBL] [Abstract][Full Text] [Related]
47. Molecular interactions between the TSH receptor and a Thyroid-stimulating monoclonal autoantibody.
Sanders J; Miguel RN; Bolton J; Bhardwaja A; Sanders P; Nakatake N; Evans M; Furmaniak J; Smith BR
Thyroid; 2007 Aug; 17(8):699-706. PubMed ID: 17725428
[TBL] [Abstract][Full Text] [Related]
48. Effects of a thyroid-stimulating human monoclonal autoantibody (M22) on functional activity of LH and FSH receptors.
Tonacchera M; Ferrarini E; Dimida A; Agretti P; De Marco G; Pinchera A; Sanders J; Evans M; Richards T; Furmaniak J; Smith BR
Thyroid; 2006 Nov; 16(11):1085-9. PubMed ID: 17123334
[TBL] [Abstract][Full Text] [Related]
49. Upon thyrotropin binding the thyrotropin receptor is internalized and localized to endosome.
Singh SP; McDonald D; Hope TJ; Prabhakar BS
Endocrinology; 2004 Feb; 145(2):1003-10. PubMed ID: 14576174
[TBL] [Abstract][Full Text] [Related]
50. [Peptide 612-627 of thyrotropin receptor and its modified derivatives as the regulators of adenylyl cyclase in the rat thyroid gland].
Shpakov AO; Shpakova EA; Tarasenko II; Derkach KV
Tsitologiia; 2014; 56(7):526-35. PubMed ID: 25696997
[TBL] [Abstract][Full Text] [Related]
51. Desensitization of adenylate cyclase in Chinese hamster ovary cells transfected with human thyroid-stimulating hormone receptor.
Tezelman S; Shaver JK; Grossman RF; Liang W; Siperstein AE; Duh QY; Clark OH
Endocrinology; 1994 Mar; 134(3):1561-9. PubMed ID: 8119199
[TBL] [Abstract][Full Text] [Related]
52. Thyrotropin, like luteinizing hormone (LH) and chorionic gonadotropin (CG), increases cAMP and inositol phosphate levels in cells with recombinant human LH/CG receptor.
Hidaka A; Minegishi T; Kohn LD
Biochem Biophys Res Commun; 1993 Oct; 196(1):187-95. PubMed ID: 8216292
[TBL] [Abstract][Full Text] [Related]
53. Suppression of thyrotropin receptor-G protein-phospholipase C coupling by activation of protein kinase C in thyroid carcinoma cells.
Broecker M; Mayr GW; Derwahl M
Endocrinology; 1997 Sep; 138(9):3787-96. PubMed ID: 9275066
[TBL] [Abstract][Full Text] [Related]
54. TSH is a negative regulator of skeletal remodeling.
Abe E; Marians RC; Yu W; Wu XB; Ando T; Li Y; Iqbal J; Eldeiry L; Rajendren G; Blair HC; Davies TF; Zaidi M
Cell; 2003 Oct; 115(2):151-62. PubMed ID: 14567913
[TBL] [Abstract][Full Text] [Related]
55. Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor.
Titus S; Neumann S; Zheng W; Southall N; Michael S; Klumpp C; Yasgar A; Shinn P; Thomas CJ; Inglese J; Gershengorn MC; Austin CP
J Biomol Screen; 2008 Feb; 13(2):120-7. PubMed ID: 18216391
[TBL] [Abstract][Full Text] [Related]
56. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.
Krieger CC; Neumann S; Place RF; Marcus-Samuels B; Gershengorn MC
J Clin Endocrinol Metab; 2015 Mar; 100(3):1071-7. PubMed ID: 25485727
[TBL] [Abstract][Full Text] [Related]
57. The thyrotropin receptor hinge region as a surrogate ligand: identification of loci contributing to the coupling of thyrotropin binding and receptor activation.
Chen CR; Salazar LM; McLachlan SM; Rapoport B
Endocrinology; 2012 Oct; 153(10):5058-67. PubMed ID: 23002040
[TBL] [Abstract][Full Text] [Related]
58. Detection of thyroid stimulating (TSAB)- and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH-receptor numbers.
Wallaschofski H; Paschke R
Clin Endocrinol (Oxf); 1999 Mar; 50(3):365-72. PubMed ID: 10435063
[TBL] [Abstract][Full Text] [Related]
59. Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway.
Park ES; Kim H; Suh JM; Park SJ; You SH; Chung HK; Lee KW; Kwon OY; Cho BY; Kim YK; Ro HK; Chung J; Shong M
Mol Endocrinol; 2000 May; 14(5):662-70. PubMed ID: 10809230
[TBL] [Abstract][Full Text] [Related]
60. Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells.
Fournes B; Monier R; Michiels F; Milgrom E; Misrahi M; Feunteun J
Oncogene; 1998 Feb; 16(8):985-90. PubMed ID: 9519872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
